# Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

> **NCT02647632** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 26 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir/Elbasvir
- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02647632
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2017-01
- **Final completion:** 2017-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02647632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02647632, "Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02647632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*